Content Rheum | IL-23

top of page

Content Rheum

Interleukin-23 Inhibition

FAQs

Click a title to watch the FAQ

Define, compare, and contrast humoral and cell-mediated immunity

Describe the IL23/IL17 axis

What is the role of the IL23/IL17 axis in rheumatic disease?

Provide Immunologic Rationale For IL23 Directed Therapy in PsA, PsO, and IBD.

Why is Binding CD64+ Important When Discussing IL23 Directed Therapy

How does axial PsA differ from AS clinically, genetically, and radiographically

Medication Review_v2.png

MEDICATION REVIEWS

Click a title to watch the review

Describe the mechanism of action of guselkumab

What is Non-Responder Imputation and How is it Utilized in Clinical Trials

How is Guselkumab dosed in PsO, PsA, and IBD

JOURNAL CLUBS

Click a title to read the journal

Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

PODCASTS

Click a title to play the podcast

The IL23/IL17 Cascade and Implications in the Pathogenesis of PsA, PsO, and IBD

CD64+ Binding: Description, Relevance, and Potential Clinical Implications

Become a RhAPP Member

bottom of page